A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects.
Reitz
A B
AB
R. W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania 19477.
Bennett
D J
DJ
Blum
P S
PS
Codd
E E
EE
Maryanoff
C A
CA
Ortegon
M E
ME
Renzi
M J
MJ
Scott
M K
MK
Shank
R P
RP
Vaught
J L
JL
D000818:Animals; D014150:Antipsychotic Agents / Q000138:chemical synthesis / Q000378:metabolism* / Q000494:pharmacology; D004285:Dogs; D006801:Humans; D015394:Molecular Structure; D010879:Piperazines / Q000138:chemical synthesis / Q000378:metabolism* / Q000494:pharmacology; D020891:Raclopride; D051381:Rats; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism*; D011954:Receptors, Dopamine / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D050637:Receptors, Dopamine D3; D011985:Receptors, Serotonin / Q000378:metabolism*; D012457:Salicylamides / Q000378:metabolism
D014150:Antipsychotic Agents; C493593:DRD3 protein, human; C493595:Drd3 protein, rat; D010879:Piperazines; D011942:Receptors, Adrenergic, alpha; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D011985:Receptors, Serotonin; D012457:Salicylamides; D020891:Raclopride; C086897:mazapertine succinate